ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in
treating non-small cell lung cancer (NSCLC). Vandetanib is a new type of agent that targets
the blood supply to a cancer tumour (through it's anti-vascular endothelial growth factor
receptor (VEGFR) properties) and the tumour cells themselves (through it's anti-endothelial
growth factor receptor (EGFR) actions). This study will look at the effects of vandetanib in
lung cancer patients who have had their cancer re-appear after treatment with standard
chemotherapy.
This clinical study will test if the vandetanib anti-VEGF and anti-EGFR characteristics can
deliver longer improved progression free survival and improved overall survival than
docetaxel (Taxotere) alone.
All patients participating this clinical study will receive treatment with docetaxel, a
commonly used treatment for recurrent non-small cell lung cancer.
In addition, some patients will also receive vandetanib (ZACTIMA), an anti-EGFR / anti-VEGF
agent.
Recent clinical research shows that vascular endothelial growth factor receptor (VEGFR)
inhibition, when used with standard chemotherapy, can lead to increased survival in advanced
non-small cell lung cancer (NSCLC) patients.
Other research shows that epidermal growth factor receptor (EGFR) inhibitors, like erlotinib
(Tarceva) can also increase overall non-small cell lung cancer survival by killing tumour
cells and stopping them from dividing.